Efficacy and safety of vorapaxar as approved for clinical use in the United States

Journal of the American Heart Association

Volumn 4, Issue 3, 2015, Pages e001505-

  Magnani, Giulia ^a   Bonaca, Marc P ^a   Braunwald, Eugene ^a   Dalby, Anthony J ^a   Fox, Keith A A ^a   Murphy, Sabina A ^a   Nicolau, José Carlos ^a   Oude Ophuis, Ton ^a   Scirica, Benjamin M ^a   Spinar, Jindrich ^a   Theroux, Pierre ^a   Morrow, David A ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

antiplatelet therapy; atherosclerosis; myocardial infarction; peripheral arterial disease; secondary prevention; vorapaxar

Indexed keywords

ANTITHROMBOCYTIC AGENT; LACTONE; PROTEINASE ACTIVATED RECEPTOR 1; PYRIDINE DERIVATIVE; VORAPAXAR;

AGED; ANTAGONISTS AND INHIBITORS; BLEEDING; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; EPIDEMIOLOGY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; ISCHEMIC ATTACK, TRANSIENT; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; SECONDARY PREVENTION; STROKE; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; DOUBLE-BLIND METHOD; DRUG APPROVAL; FEMALE; HEMORRHAGE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIER ESTIMATE; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; STROKE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85016499293     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001505     Document Type: Article

References (0)